Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
about
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@en
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@nl
type
label
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@en
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@nl
prefLabel
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@en
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant.
@nl
P2093
P50
P1476
Dual mTOR Kinase Inhibitor MLN ...... to Trastuzumab or Fulvestrant
@en
P2093
Chun-Yu Liu
Courtney A Vito
Hang-Kai Hsu
Karineh Petrossian
Laura Kruper
Masaya Kai
Noriko Kanaya
Pei-Yin Hsu
Peiguo Chu
P304
P356
10.1158/1078-0432.CCR-17-1983
P407
P577
2017-10-27T00:00:00Z